Obesity Pillars,
Journal Year:
2023,
Volume and Issue:
5, P. 100059 - 100059
Published: Feb. 21, 2023
Once
thought
to
be
primarily
a
result
of
lifestyle,
it
is
now
known
that
obesity
has
significant
genetic
components.
Dozens
genes
have
been
linked
obesity,
and
office-based
testing
for
obesity-associated
readily
available.
As
both
pharmacotherapy
become
more
accessible,
pharmacogenetic
personalization
becoming
reality.
In
this
case
report,
patient
with
PLXNA4
polymorphism
had
superior
weight
loss
response
phentermine/topiramate
therapy
than
previously
reported
in
the
literature.
Thus,
variants
may
provide
basis
patient's
cardiovascular
risk
factor
reduction.
Journal of clinical lipidology,
Journal Year:
2024,
Volume and Issue:
18(3), P. e320 - e350
Published: April 24, 2024
BACKGROUNDThis
joint
expert
review
by
the
Obesity
Medicine
Association
(OMA)
and
National
Lipid
(NLA)
provides
clinicians
an
overview
of
pathophysiologic
clinical
considerations
regarding
obesity,
dyslipidemia,
cardiovascular
disease
(CVD)
risk.METHODSThis
is
based
upon
scientific
evidence,
perspectives
authors,
peer
OMA
NLA
leadership.RESULTSAmong
individuals
with
adipose
tissue
may
store
over
50%
total
body
free
cholesterol.
Triglycerides
represent
up
to
99%
lipid
species
in
tissue.
The
potential
for
expansion
accounts
greatest
weight
variance
among
most
individuals,
percent
fat
ranging
from
less
than
5%
60%.
While
population
studies
suggest
a
modest
increase
blood
low-density
lipoprotein
cholesterol
(LDL-C)
levels
excess
adiposity,
adiposopathic
dyslipidemia
pattern
often
described
adiposity
includes
elevated
triglycerides,
reduced
high
density
(HDL-C),
increased
non-HDL-C,
apolipoprotein
B,
LDL
particle
concentration,
small,
dense
particles.CONCLUSIONSObesity
increases
CVD
risk,
at
least
partially
due
promotion
adiposopathic,
atherogenic
profile.
also
worsens
other
cardiometabolic
risk
factors.
Among
patients
interventions
that
reduce
improve
outcomes
are
generally
associated
improved
levels.
Given
improvement
LDL-C
reduction
overweight
or
early
treat
both
(LDL-C
and/or
non-HDL-C)
priorities
reducing
CVD.
This
risk.
leadership.
particles.
Obesity Pillars,
Journal Year:
2024,
Volume and Issue:
10, P. 100108 - 100108
Published: March 12, 2024
This
joint
expert
review
by
the
Obesity
Medicine
Association
(OMA)
and
National
Lipid
(NLA)
provides
clinicians
an
overview
of
pathophysiologic
clinical
considerations
regarding
obesity,
dyslipidemia,
cardiovascular
disease
(CVD)
risk.
is
based
upon
scientific
evidence,
perspectives
authors,
peer
OMA
NLA
leadership.
Among
individuals
with
adipose
tissue
may
store
over
50%
total
body
free
cholesterol.
Triglycerides
represent
up
to
99%
lipid
species
in
tissue.
The
potential
for
expansion
accounts
greatest
weight
variance
among
most
individuals,
percent
fat
ranging
from
less
than
5%
60%.
While
population
studies
suggest
a
modest
increase
blood
low-density
lipoprotein
cholesterol
(LDL-C)
levels
excess
adiposity,
adiposopathic
dyslipidemia
pattern
often
described
adiposity
includes
elevated
triglycerides,
reduced
high
density
(HDL-C),
increased
non-HDL-C,
apolipoprotein
B,
LDL
particle
concentration,
small,
dense
particles.
increases
CVD
risk,
at
least
partially
due
promotion
adiposopathic,
atherogenic
profile.
also
worsens
other
cardiometabolic
risk
factors.
patients
interventions
that
reduce
improve
outcomes
are
generally
associated
improved
levels.
Given
improvement
LDL-C
reduction
overweight
or
early
treat
both
(LDL-C
and/or
non-HDL-C)
priorities
reducing
CVD.
Obesity,
Journal Year:
2024,
Volume and Issue:
32(9), P. 1613 - 1631
Published: June 10, 2024
The
improved
efficacy
and
generally
favorable
safety
profile
of
recently
approved
emerging
antiobesity
medications
(AOMs),
which
result
in
an
average
weight
reduction
≥15%,
represent
significant
advancement
the
treatment
obesity.
This
narrative
review
aims
to
provide
practical
evidence-based
recommendations
for
nutritional
assessment,
management,
monitoring
patients
treated
with
AOMs.
Prior
treatment,
clinicians
can
identify
preexisting
risk
factors
counsel
their
on
recommended
intakes
protein,
dietary
fiber,
micronutrients,
fluids.
During
AOMs,
ongoing
facilitate
early
recognition
management
gastrointestinal
symptoms
or
inadequate
nutrient
fluid
intake.
Attention
should
also
be
paid
other
that
impact
response
quality
life,
such
as
physical
activity
social
emotional
health.
In
context
play
active
role
supporting
obesity
improve
health
well-being
promote
optimal
medical
outcomes.
Obesity Pillars,
Journal Year:
2023,
Volume and Issue:
5, P. 100056 - 100056
Published: Jan. 28, 2023
This
Obesity
Medicine
Association
(OMA)
Clinical
Practice
Statement
(CPS)
is
intended
to
provide
clinicians
an
overview
of
type
2
diabetes
mellitus
(T2DM),
obesity-related
cardiometabolic
risk
factor.
Obesity Reviews,
Journal Year:
2024,
Volume and Issue:
25(5)
Published: Feb. 6, 2024
Summary
Glucagon‐like
peptide
1
(GLP‐1)
receptor
agonists
are
revolutionizing
obesity
and
type
2
diabetes
treatment,
delivering
remarkable
weight
loss
outcomes.
These
medications,
leveraging
the
effects
of
insulin‐regulating
hormone
GLP‐1
via
actions
on
peripheral
central
nervous
system
targets,
have
raised
hopes
with
their
bariatric
surgery‐rivaling
results.
However,
questions
remain
about
long‐term
safety
efficacy.
Drawing
from
our
expertise
in
medicine
psychiatry,
we
reflect
upon
experiences
clinical
use
these
medications
delve
into
nuanced
challenges
risks
they
pose,
particularly
for
those
prone
to
disordered
eating
or
diagnosed
rare
genetic
diseases
obesity.
We
contend
that
effectively
managing
within
this
“danger
zone”
necessitates
(1)
proactive
screening
continuous
monitoring
eating,
(2)
vigilant
appetite‐related
maladaptive
responses,
including
food
aversion
dehydration,
(3)
ongoing
assessment
broader
health
impacts.
A
multifaceted,
interdisciplinary
approach
melds
medical,
psychological,
dietary,
behavioral
strategies
is
crucial
tailored
thorough
care
each
patient.
Obesity Pillars,
Journal Year:
2023,
Volume and Issue:
8, P. 100092 - 100092
Published: Oct. 19, 2023
This
Obesity
Medicine
Association
(OMA)
Clinical
Practice
Statement
(CPS)
is
intended
to
provide
clinicians
with
an
overview
on
obesity,
thrombosis,
venous
disease,
lymphatic
and
lipedema.
Obesity Pillars,
Journal Year:
2024,
Volume and Issue:
11, P. 100121 - 100121
Published: July 25, 2024
Obesity
and
type
2
diabetes
mellitus
(T2DM)
are
increasingly
common
in
the
United
States
worldwide.
Because
both
conditions
associated
with
serious
health
consequences,
weight
reduction
is
recommended
by
professional
medical
nutrition
societies
to
improve
outcomes.
Due
striking
efficacy
of
glucagon-like
peptide
receptor
agonists
(GLP-1RAs)
dual
mechanism
glucose-dependent
insulinotropic
polypeptide/glucagon-like
(GIP/GLP-1RAs)
for
glycemic
control,
there
increased
utilization
patients
obesity
and/or
T2DM.
Yet,
impact
these
medications
on
dietary
intake
less
understood.
This
narrative
literature
review
summarizes
clinical
studies
quantifying
characterizing
people
T2DM
using
GLP-1
or
GIP/GLP-1
RAs.
Though
data
from
reveal
that
total
caloric
was
reduced
16–39
%,
few
evaluated
actual
composition
diet.
Further
research
needed
understand
unique
nutritional
needs
adults
GIP/GLP-1RAs
support
development
guidelines
individuals.
